East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians by Zhou, Wei & Christiani, David C.
 
East meets West: ethnic differences in epidemiology and clinical
behaviors of lung cancer between East Asians and Caucasians
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Zhou, Wei, and David C. Christiani. 2011. “East meets West:
ethnic differences in epidemiology and clinical behaviors of lung
cancer between East Asians and Caucasians.” Chinese Journal of
Cancer 30 (5): 287-292. doi:10.5732/cjc.011.10106.
http://dx.doi.org/10.5732/cjc.011.10106.
Published Version doi:10.5732/cjc.011.10106
Accessed February 16, 2015 12:12:22 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12406874
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAA1 Molecular Epidemiology Research, Global Outcomes 
Research, Pfizer Oncology, Collegeville, PA 19426, USA; 
2 Departments 
of  Epidemiology  and  Environmental  Health,  Harvard  School  of  Public 
Health,  Boston,  MA  02115,  USA; 
3 Department  of  Medicine, 
Massachusetts General Hospital, Harvard Medical School, Boston, MA 
02115, USA. 
Wei  Zhou,  Molecular  Epidemiology  Research, 
Pfizer  Oncology,  500  Arcola  Road,  C5309,  Collegeville,  PA  19426鄄  
3982, USA. Email: wzhou28@gmail.com. 
Chinese  Anti鄄   Cancer Association  CACA 
Chinese Journal of Cancer 
www.cjcsysu.com 
Wei Zhou 
1 and David C. Christiani 
2,3 
Abstract 
Lung cancer is the leading cause of cancer death worldwide, with large variation of the incidence and 
mortality across regions. Although the mortality of lung cancer has been decreasing, or steady in the US, 
it has been increasing in Asia for the past two decades. Smoking is the leading cause of lung cancer, and 
other risk factors such as indoor coal burning, cooking fumes, and infections may play important roles in 
the  development  of  lung  cancer  among  Asian  never  smoking  women.  The  median  age  of  diagnosis  in 
Asian patients with lung cancer is generally younger  than Caucasian patients,  particularly among  never鄄  
smokers. Asians and Caucasians may have different genetic susceptibilities to lung cancer, as evidenced 
from  candidate  polymorphisms  and  genome鄄   wide  association  studies.  Recent  epidemiologic  studies  and 
clinical  trials  have  shown  consistently  that  Asian  ethnicity  is  a  favorable  prognostic  factor  for  overall 
survival in non-small cell lung cancer  (NSCLC), independent of smoking status. Compared with Caucasian 
patients  with  NSCLC,  East  Asian  patients  have  a  much  higher  prevalence  of  epidermal  growth  factor 
receptor (EGFR) mutation (approximately 30% vs. 7%, predominantly among patients with adenocarcinoma 
and never鄄   smokers), a lower prevalence of K鄄   Ras mutation  (less than 10% vs. 18%, predominantly among 
patients  with  adenocarcinoma  and  smokers),  and  higher  proportion  of  patients  who  are  responsive 
to  EGFR  tyrosine  kinase  inhibitors.  The  ethnic  differences  in  epidemiology  and  clinical  behaviors 
should  be  taken  into  account  when  conducting  global  clinical  trials  that  include  different  ethnic 
populations. 
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Lung cancer is the most commonly diagnosed 
cancer and the leading cause of cancer death worldwide. 
Lung cancer accounted for 13% (1.6 million) of the total 
cancer cases and 18% (1.4 million) of the cancer deaths 
in 2008 
[1] . There is a large variation of the incidence and 
mortality rate of lung caner in the world. In males, the 
highest lung cancer incidence rates are in 
Central/Eastern and Southern Europe (age­standardized 
rate, ASR, of 57 and 49 per 100 000, respectively), North 
America (ASR of 48.5 per 100 000), and Eastern Asia 
(ASR of 45 per 100 000). In females, the highest lung 
cancer incidence rates are found in North America (ASR 
of 35.8 per 100000), Northern Europe (ASR of 21.8 per 
100000), and Eastern Asia (ASR of 19.9 per 100000) 
[1] . 
The different incidence between men and women 
explains that in the US, approximately 45% of patients 
with NSCLC are women. However, in Eastern Asia, only 
25% to 30% of patients with lung cancer are women 
[2,3] . 
Epidemiology,  Environment,  and  Ge鄄  
netic Susceptibility of  Lung Cancer Pa鄄  
tients in Asia and the US 
There are other differences in characteristics of lung 
cancer patients between Asia and the US. Compared 
with patients in the US, Asian patients have generally a 
younger age of onset. In addition, the median age of 
Asian never­smoker patients (defined as never smoked 
or smoked less than 100 cigarettes in the lifetime) is 
significantly younger than ever­smoker patients; whereas 
in the US, the median age of never­smoker patients is 
Review 
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significantly older than ever­smoker patients 
[3] . 
Smoking, the leading cause of lung cancer, 
accounts for 80% of the worldwide lung cancer burden in 
males and at least 50% of the burden in females 
[1] . In 
the US, approximately 10% of patients with lung cancer 
are never­smokers. In Asia, more than 30% of patients 
with lung cancer are never­smokers, and half or more 
lung cancer in women occur in never­smokers 
[3,4] , 
suggesting that other risk factors may play an important 
role in the development of lung cancer. 
Although cigarette smoking has peaked and 
declined in the US and several other areas, it has 
dramatically increased in the past two decades, and has 
yet to peak, in China and other developing countries [5] . 
Approximately 67% of males and 4% of females over 15 
years of age in China are smokers, and a total of over 
320 million Chinese smokers represents about one­third 
of all smokers worldwide 
[4] . Correspondingly, in the US, 
for the past two decades, the incidence and mortality of 
lung cancer have been decreasing among males and 
have remained steady among females. In China, the 
mortality of lung cancer has doubled between the 1970s 
and 1990s. Despite the lower prevalence of smoking, 
Chinese females have a higher prevalence of lung 
cancer (21.3 cases per 100000 females) than do females 
in certain European countries such as Germany (16.4 
cases per 100 000 females) and Italy (11.4 cases per 
100 000 females), with an adult smoking prevalence of 
about 20% 
[1] . 
Other known risk factors for lung cancer include 
second hand smoking, diet and food supplements, 
alcohol drinking, exercise and physical activity, air 
pollution, and occupational/environmental exposure 
[5,6] . 
Indoor air pollution, mainly due to coal burning, may 
account for 13% of lung cancer in men and 17% of lung 
cancer in women in China 
[7] . For Chinese never smoking 
women, indoor cooking fumes may also contribute to the 
development of lung cancer 
[6] . In addition, infections such 
as tuberculosis and human papillomavirus may 
contribute to the development of lung cancer among 
Asian women 
[6] . 
In addition to different environmental exposures, 
family history and genetic susceptibility play important 
roles in the development of lung cancer 
[6] . Allele or 
genotype frequencies of genes in tobacco and drug 
metabolism (e.g.  ,  , 
), DNA repair (e.g. 
), and inflammation (e.g.  ) 
may vary between different ethnic populations. 
Genome­wide association studies of lung cancer 
reported in predominantly Caucasian populations have 
identified three regions on chromosomes 5p15.33, 
6p21.33, and 15q25 that have achieved genome­wide 
significance with  values of 10 
­7  or lower 
[8­11] . A recent 
study concluded that common genetic variants in the 
TERT­CLPTM1L locus on chromosome 5p15.33 
(rs2736100) are associated with risk for lung 
adenocarcinoma in never smoking Asian women, with 
substantially higher effect sizes than those previously 
reported in European smokers. However, there was no 
convincing evidence for association at chromosome 
6p21.33 or 15q25 for lung cancer overall or for the 
adenocarcinoma subtype 
[12] . It is not clear whether the 
differences are due to different smoking status, or 
ethnicity, or some other variable(s). 
Survival  and  Prognostic  Differences 
Between  Lung  Cancer  Patients  in  Asia 
and the US 
Several large epidemiologic studies suggested that 
Asian ethnicity is a favorable prognostic factor for overall 
survival (OS) of patients with non­small cell lung cancer 
(NSCLC, which accounts for ~85% of all lung cancers) 
and is independent of smoking status 
[2,3,13] . A recent 
retrospective population­based analysis of 15185 
Japanese and 13 332 US Caucasian NSCLC patients 
treated between 1991 and 2001 suggested that 
Japanese ethnicity [vs. Caucasian: hazard ratio (HR) = 
0.937, 95% confidence interval (CI)= 0.898­0.978,  = 
0.003] and never­smoker status (vs. ever­smoker: HR = 
0.947, 95% CI = 0.909­0.987,  = 0.010) are 
independent favorable factors for OS in addition to 
younger age, female gender, early stage, and treatment 
received 
[3] . The results were confirmed by a retrospective 
population­based analysis of 4622 Korean and 8846 US 
Caucasian NSCLC patients, with an adjusted hazard 
ratio of 0.869 (  < 0.0001) for Korean vs. Caucasian 
patients 
[2] . Another retrospective population­based study 
of 20 140 NSCLC patients from the cancer surveillance 
programs of three Southern California counties 
suggested that even within the US, Asian ethnicity is an 
independent and favorable prognostic factor for OS (vs. 
non­Asian: HR = 0.861, 95% CI = 0.808­0.918), among 
both smokers (vs. non­Asian: HR = 0.867, 95% CI = 
0.807­0.931) and never­smokers (vs. non­Asian: HR = 
0.841, 95% CI = 0.728­0.971), adjusting for covariates 
such as age, gender, smoking status, pathology, and 
treatment 
[13] . Similar results were observed after 
stratification by stage. It is not clear whether these Asian 
American NSCLC patients were born in their native 
countries, and whether this ethnic difference will hold 
after the first generation. In another study with 1124 
Asian American NSCLC patients including 5 major Asian 
American subgroups (Filipino, Vietnamese, Japanese, 
Chinese, and Korean), there was no statistically 
significant difference in clinicopathologic features or 
survival outcome between individual Asian American 
subgroups when analyzed according to smoking status, 
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nor survival difference between never­smokers and 
ever­smokers (11 vs. 10 months;  = 0.30) 
[14] . Except for 
Japanese American, most of the other ethnicity 
subgroups were born in their native countries. Analyses 
on Japanese patients suggested that the proportion of 
Japanese never­smokers was higher among native 
Japanese (17.2%) than non­native Japanese (11.6%) 
NSCLC patients 
[14] . 
In addition to epidemiologic studies, a recent 
randomized clinical trial of first­line chemotherapy among 
advanced epidermal growth factor receptor (EGFR)鄄  
expressing NSCLC patients showed that Asian patients 
have about 10 months longer OS compared with 
Caucasian patients regardless of treatment received, 
which is partially explained by different demographics 
(e.g. younger age of onset, higher proportion of 
never­smokers) and more frequent use of EGFR tyrosine 
kinase inhibitors (TKIs) in Asian patients (61% in Asian 
vs. 17% in Caucasian) in subsequent lines of treatment 
[15] . 
Another study analyzed results from three phase III trials 
suggesting a 3­ to 5­month OS improvement in Japanese 
NSCLC patients compared to US patients who received 
carboplatin/paclitaxel as first­line treatment (12 or 14 
months vs. 9 months;  = 0.0006). It has been suggested 
that differences in allelic distribution for genes involved in 
paclitaxel distribution and deposition (  and 
) or DNA repair (  and  ) may 
contribute to the different outcome between Japanese 
and US patients 
[16] . 
Somatic  Mutations  Among  Asian  and 
US Patients with Lung Cancer 
Treatment of NSCLC, particularly adenocarcinoma, 
is in the era of personalized medicine, with the focus on 
the development of innovative treatment options, 
particularly new target­based therapies directed against 
key signaling pathways involved in lung cancer growth 
and malignant progression. Many biomarkers, including 
and  somatic mutations, 
mRNA expression, and  translocation, have 
been tested for patient screening in clinical trials and/or 
clinical treatment. Among these,  and 
mutations have clearly demonstrated different 
characteristics between NSCLC patients in Asian and 
Caucasian populations 
[17­20] . 
EGFR mutation 
EGFR, a cell membrane receptor with tyrosine 
kinase activity, is expressed in most patients with 
NSCLC and plays an important role in cellular 
proliferation, inhibition of apoptosis, angiogenesis, 
metastatic potential, and chemoresistance. 
mutation has been proven to be a predictive biomarker 
for EGFR­TKIs, both for gefitinib and erlotinib, among 
both Asian and Western NSCLC patients. The IRESSA 
Pan­Asia Study (IPASS) phase III trial compared 
first­line carboplatin and paclitaxel with gefitinib in East 
Asian never­smokers or former light smokers with lung 
adenocarcinoma 
[21] . The trial demonstrated the superiority 
of gefitinib compared with carboplatin and paclitaxel in 
overall response rate (RR, 43.0% vs. 32.2%; odds ratio 
= 1.59, 95% CI = 1.25­2.01,  < 0.001), progression­ 
free survival (PFS, HR = 0.74, 95% CI= 0.65­0.85,  < 
0.001), and quality of life, as well as a lower rate of 
toxicity in the intent­to­treat patient population. In the 
subgroup of patients with an  mutation, the PFS 
was significantly longer in the gefitinib arm than in the 
carboplatin and paclitaxel arm (HR = 0.48, 95% CI = 
0.36­0.64,  < 0.001). In contrast, in patients with 
wild­type  , the PFS was significantly shorter in the 
gefitinib arm than in the carboplatin and paclitaxel arm 
(HR = 2.85, 95% CI = 2.05­3.98,  < 0.001). The final 
analysis of IPASS study showed that median OS was 
similar between gefitinib and carboplatin/paclitaxel arms 
in the overall population (18.8 vs. 17.4 months, HR = 
0.90, 95% CI = 0.79­1.02,  = 0.11), in  mutant 
patients (21.6 vs. 21.9 months, HR = 1.00, 95% CI = 
0.76­1.33), in  wild­type patients (11.2 vs. 12.7 
months, HR = 1.18, 95% CI = 0.86­1.63), and in 
patients whose  mutation status was unknown 
(18.9 vs. 17.2 months, HR = 0.82, 95% CI = 0.70­0.96). 
Patients with  mutation had better outcomes 
(median OS, 22 months) than those with wild­type 
(median OS, 11­12 months), regardless of which 
treatment arm they were in 
[22] . 
In another phase III OPTIMAL study presented by 
Zhou  . 
[23]  at the 2010 European Society for Medical 
Oncology (ESMO) conference, which randomized 165 
Asian patients with advanced NSCLC to first­line erlotinib 
or gemcitabine/carboplatin chemotherapy doublet, the 
primary endpoint of PFS was 13.1 months in the erlotinib 
arm compared to only 4.6 months (HR of 0.16,  < 
0.0001) in the chemotherapy doublet arm. The benefit 
provided by treatment with erlotinib was consistent in all 
subgroups stratified by age, smoking status, and gender. 
In addition to Asian studies, a recent press release 
in January 2011 announced that in the interim analysis of 
the phase III EURTAC trial by the Spanish Lung Cancer 
Group with researchers in France and Italy, erlotinib 
significantly extended PFS among newly diagnosed 
NSCLC patients with EGFR­activating mutations when 
compared with a platinum­based chemotherapy regimen. 
It is the first phase III study to show a PFS benefit with 
first­line treatment in a Western population with 
advanced NSCLC harboring  mutations, with the 
full data to be presented or published soon. An Online 
Tumor Registry of five clinical trials from the US and 
Wei Zhou et al.  Ethnic differences of lung cancer 
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Europe, in which chemotherapy­naive patients with 
advanced NSCLC were treated with an EGFR­TKI 
(gefitinib or erlotinib), 56 (67%)  mutant patients 
achieved an objective response, with a median PFS of 
11.8 months and a median OS of 23.9 months. For the 
83 patients with wild­type  and wild­type  , 
the RR was 5%, the median PFS was 3.1 months, and 
the median OS was 11.8 months. Among the 41 patients 
with wild­type  and mutated  , RR was 0%, 
PFS was 3.3 months, and median OS was 13 months. 
Patients with  exon 19 deletions had a longer PFS 
(14.6 vs. 9.7 months,  = 0.02) and OS (30.8 vs. 
14.8 months,  < 0.001) than those with the L858R 
mutation  [24] . 
Several demographic and pathological factors are 
associated with  mutation prevalence. 
mutation is mainly observed among patients with 
adenocarcionoma, never­smokers, and Eastern Asian 
ethnicity. Among Asian patients, the overall prevalence 
of  mutations (i.e. exons 18­22) is approximately 
30% overall, 47% among patients with adenocarcinoma, 
and 56% among never­smokers. Among Caucasians, 
the average  mutation prevalence is approximately 
7% overall, 13% among patients with adenocarcinoma, 
and 35% among never­smokers 
[20] . The reason for the 
high frequency of  mutations in Asian patients is 
unclear, and it is suggested that the CA simple 
sequence repeat 1 (CA­SSR1), a highly polymorphic 
locus containing 14 to 21 CA dinucleotide repeats, and 
polymorphisms in the  promoter regions may play 
an important role. Studies have suggested that many 
Asians have polymorphic types that lead to a decreased 
intrinsic production of EGFR protein. If a certain critical 
level of EGFR is required to drive the cell toward a 
malignant phenotype, another mechanism including 
activating mutations of  and/or autonomously 
activating downstream signaling may be required for the 
development of lung cancer among Asians 
[19,20] . 
K鄄   Ras mutation 
The Ras proteins belong to the small guanosine 
triphosphatase (GTPase) superfamily. Each  gene 
has a predilection to specific tumors, with 
predominantly found in colorectal, lung, pancreatic, 
ovarian, endometrial, gastric, and brain cancers, 
in bladder cancer, and  in melanoma and 
leukemia. More than 95% of  mutations are in 
codons 12/13 of exon 2.  mutation results in 
activation of Ras protein, inhibition of GTPase activity, 
resistance to upstream inhibitors, and resistance to 
EGFR inhibitors. 
The overall  mutation prevalence in patients 
with NSCLC is approximately 16% (or 18% among 
Caucasian populations), based on two recent meta­ 
analyses of 22 studies with 1470 NSCLC patients treated 
with EGFR­TKIs 
[17,18] .  mutation is predominantly 
observed among Caucasian patients with 
adenocarcinoma (~26% vs. 16% among patients with 
NSCLC of other cell types, and very uncommon among 
patients with squamous cell carcinoma) and 
ever­smokers (25% vs. 6% among never­smokers) 
[17,18] . 
A recent study on 482 patients with lung 
adenocarcinoma (mainly Caucasians) suggested a 15% 
of  mutation prevalence among never­smokers, 
22% among former smokers, and 25% among current 
smokers (  = 0.12) 
[25] . In addition, never­smokers were 
significantly more likely than former or current smokers 
to have a transition mutation (G to A) rather than the 
transversion mutations (G to T or G to C) known to be 
smoking­related (  < 0.0001) 
[25] . Among Eastern Asian 
patients with NSCLC,  mutation prevalence is 
generally less than 10% and is very rare among 
squamous cell carcinoma and never­smoker patients 
[26] . 
Asbestos exposure may be associated with 
mutation; however, data are limited. 
There are inconclusive results on whether 
mutation is a prognostic or predictive factor of advanced 
NSCLC treated with chemotherapy 
[27] .  mutant 
patients with NSCLC do not generally respond to 
EGFR­TKIs, and the predictive power of 
mutations for EGFR­TKIs sensitivity was higher in Asians 
than in Caucasians 
[18] . However, due to a mutually 
exclusive relationship between  and 
mutation, and no survival difference between mutant and 
wild­type K­Ras among EGFR wild­type patients with 
NSCLC 
[24] , the clinical usefulness of  mutation as a 
predictor of EGFR­TKIs sensitivity in patients with 
NSCLC is limited 
[18] . 
EML4鄄   ALK translocation 
A recent breakthrough in NSCLC treatment is the 
discovery of the  fusion­type tyrosine kinase in 
patients with NSCLC (mostly adenocarcinoma) and the 
dramatic response of 
+  patients to crizotinib in 
clinical trials 
[28,29] . Replacement of the extracellular and 
trans­membrane domain of ALK with a region of EML4 
results in constitutive dimerization of the kinase domain 
and thereby a consequent increase in its catalytic 
activity [28] . In a phase I study with 82 advanced NSCLC 
patients who have mostly failed multiple lines of therapy, 
the overall response rate of  patients to 
crizotinib was 57% (46 confirmed partial responses and 
1 confirmed complete response), and 27 patients (33%) 
had stable disease; 63 patients (77%) were continuing to 
receive crizotinib at the time of data cutoff, and the 
estimated 6­month progression­free survival rate was 
72% , with no median for the study reached [29] . It is 
concluded that the inhibition of ALK in lung tumors with 
Wei Zhou et al.  Ethnic differences of lung cancer 
290Chin J Cancer; 2011; Vol. 30 Issue 5  www.cjcsysu.com 
咱1暂 
咱2暂 
咱3暂 
咱4暂 
咱5暂 
咱6暂 
咱7暂 
咱8暂 
咱9暂 
咱10暂 
咱11暂 
咱12暂 
咱13暂 
咱14暂 
咱15暂 
咱16暂 
咱17暂 
the ALK rearrangement resulted in tumor shrinkage or 
stable disease in most patients. 
The overall prevalence of  translocation 
among patients with NSCLC is 3% to 5% , and 
translocation is mainly observed among patients 
who are typically never or light smokers, 
adenocarcinoma, younger age of onset, and wild­type 
(e.g. mutually exclusive with  and 
mutations) 
[28,30,31] . There is no strong evidence to 
suggest an ethnic difference of  translocation 
among patients with NSCLC. Because Eastern Asian 
patients with NSCLC have higher proportion of 
never­smokers and younger age of onset, it is likely that 
a higher prevalence of ALK  +  may be observed among 
Eastern Asian patients than Caucasian patients. 
Conclusions 
Asian and Western patients with lung cancer have 
different characteristics for epidemiology (e.g. risk 
factors, demographics, and genetic susceptibility), 
clinical presentation, tumor biomarkers (e.g.  and 
mutation), response to target therapies, and 
prognosis. The exact mechanisms behind these 
differences are not clear. These ethnic differences 
should be taken into account when conducting global 
clinical trials that include different ethnic populations, 
where stratified analysis by race/ethnicity may need to 
be performed, and studies among Asian patients may 
need to be prioritized. In addition, Asia needs a guideline 
for the management of NSCLC because of differences in 
medical care, medical care insurance, ethnic variation, 
and drug approval lag within Asian countries compared 
with Western countries. It is suggested that Asian 
collaborative trials on treatment of NSCLC patients need 
to be started promptly to generate data from this 
important part of the world  [32] . 
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